Eliglustat approval sheet

Pharmacy Policy Bulletin Title: Gaucher Disease agents Policy #: Rx.01.161 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications may be subject to precertification, age, quantity, or formulary restrictions (ie limits on non-preferred drugs).

Cerdelga (eliglustat) 84 mg capsule 82700040600120 M, N, O, Y 2 capsules Zavesca (miglustat)a 100 mg capsule 82700070000120 M, N, O, Y 3 capsules a- generic available and included in program PRIOR AUTHORIZATION CRITERIA FOR APPROVAL Initial Evaluation Cerdelga (eliglustat) or Zavesca (miglustat) will be approved when the following are met: 1.3. PHARMACEUTICAL FORM . Insulin lispro Sanofi 100 units /ml solution for injection in vial Solution for injection (injection) . Insulin lispro Sanofi 100 units /ml solution for injection in cartridge

Cerdelga (eliglustat) 84 mg capsule 82700040600120 M, N, O, Y 2 capsules Zavesca (miglustat)a 100 mg capsule 82700070000120 M, N, O, Y 3 capsules a- generic available and included in program PRIOR AUTHORIZATION CRITERIA FOR APPROVAL Initial Evaluation Target Agent will be approved when ALL of the following are met: 1.Cerezyme® is an enzyme replacement therapy (ERT), that treats pediatric and adult patients with Gaucher disease type 1. Learn about Cerezyme® diagnosis, dosing, safety and support resources.Safety Data Sheet 1. PRODUCT AND COMPANY IDENTIFICATION 1.1 Product identifier Product name : Eliglustat (hemitartrate) Catalog No. : HY-14885A CAS No. : 928659-70-5 1.2 Relevant identified uses of the substance or mixture and uses advised against Identified uses : Laboratory chemicals, manufacture of substances.

Do you know that Type 2 classification of von Willebrand Disease is the second most common form of this disease? Do you know that the signs and symptoms assessed in a patient with Hypovolemia are directly associated with the amount of volume lost from the body? Jan 30, 2015 · Data exclusivity for medicinal products in Europe...8+2+1 approach Data exclusivity for medicinal products in Europe The pharmaceutical sector is heavily regulated, with significant costs associated with both developing a new medicinal product and generating the data required to get a product to market. The most common form of Gaucher disease, type 1, does not affect the brain or nervous system. About eliglustat tartrate. Eliglustat tartrate, a novel glucosylceramide analog given orally, is designed to partially inhibit the enzyme glucosylceramide synthase, which results in reduced production of glucosylceramide. The most common form of Gaucher disease type 1, generally does not affect the brain. About Cerdelga® Cerdelga® (eliglustat), a novel glucosylceramide analog given orally, was designed to partially inhibit the enzyme glucosylceramide synthase, which results in reduced production of glucosylceramide.